Conclusively, these data support the compelling potential in coordinated targeting of TRPM8 and α3β4-nAChRs for the treatment of the related epidemics of obesity, type 2 diabetes, and fatty liver disease. The gene discussed is TRPM8; the disease is obesity due to melanocortin 4 receptor deficiency.